TrkA (Tropomyosin Receptor Kinase A) (NTRK1)

📖 Wiki Page

protein1293 wordssynced 2026-04-02

TrkA (Tropomyosin Receptor Kinase A)

Overview

Trka (Tropomyosin Receptor Kinase A) (Ntrk1) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

<div class="infobox infobox-protein"> [@chao2003]
<table> [@mufson2003]
<tr><th colspan="2" style="background:#f0f0f0;">TrkA (Tropomyosin Receptor Kinase A)</th></tr> [@tuszynski2005]
<tr><td><b>Gene</b></td><td>[NTRK1](/genes/ntrk1) (NTRK1)</td></tr> [@lee2015]
<tr><td><b>UniProt ID</b></td><td><a href="https://www.uniprot.org/uniprot/P04629" target="_blank">P04629</a></td></tr> [@longo2014]
<tr><td><b>PDB IDs</b></td><td>1NDC, 1WWW, 4GT4, 4GT5</td></tr> [@weimar1998]
<tr><td><b>Molecular Weight</td><td>140 kDa (full-length), 76 kDa (mature form)</td></tr> [@indo2001]
<tr><td><b>Subcellular Localization</b></td><td>Cell membrane, endosomes, nucleus</td></tr>
<tr><td><b>Protein Family</b></td><td>Trk family of receptor tyrosine kinases</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>1q21-q22</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Congenital Insensitivity to Pain with Anhidrosis (CIPA), Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

Introduction

...

TrkA (Tropomyosin Receptor Kinase A)

Overview

Introduction

TrkA (Tropomyosin Receptor Kinase A), encoded by the NTRK1 gene, is a member of the Trk family of receptor tyrosine kinases that serves as the primary receptor for nerve growth factor (NGF). TrkA plays a critical role in the development, survival, and function of specific neuronal populations, particularly nociceptive [neurons](/entities/neurons), sympathetic neurons, and cholinergic neurons in the basal forebrain[1]. Due to its pivotal role in neuronal survival, TrkA has emerged as a significant therapeutic target in neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD).

Structure

TrkA is a transmembrane receptor tyrosine kinase composed of multiple distinct domains that mediate ligand binding, dimerization, and signal transduction:

Extracellular Domain

Leucine-rich motifs (LRRs): Coordinate NGF binding with high affinity
Cysteine-rich domains: Stabilize the receptor-ligand complex
Immunoglobulin-like domains: Provide additional ligand interaction surfaces

Transmembrane Domain

Single alpha-helical transmembrane segment
Anchors the receptor in the lipid bilayer

Intracellular Domain

Tyrosine kinase domain: Catalyzes autophosphorylation upon activation
Multiple tyrosine residues: Serve as docking sites for downstream signaling adaptors
C-terminal tail: Regulates kinase activity and protein interactions

Activation Mechanism

NGF binding induces TrkA dimerization, bringing intracellular kinase domains into proximity for trans-autophosphorylation. Phosphorylated tyrosine residues in the activation loop increase catalytic activity, while those in the C-terminal tail create docking sites for SH2 domain-containing proteins[2].

Normal Physiological Function

Neuronal Survival and Differentiation

TrkA mediates the trophic effects of NGF through activation of multiple downstream signaling cascades:

PI3K/Akt Pathway: Promotes neuronal survival through Akt-mediated phosphorylation of BAD, caspase-9, and transcription factors

MAPK/ERK Pathway: Regulates neuronal differentiation, synaptic plasticity, and gene expression

PLC-gamma Pathway: Modulates calcium signaling, gene transcription, and synaptic function

Tissue-Specific Functions

Nociceptors: TrkA-expressing neurons mediate pain sensation and thermal perception
Sympathetic neurons: Essential for development and maintenance of sympathetic nervous system
Basal forebrain cholinergic neurons (BFCNs): Critical for cognitive function and memory

Non-Neuronal Functions

TrkA is also expressed in:

Immune cells (T cells, B cells, mast cells)
Epithelial cells
Endothelial cells
Certain cancer cells

Role in Neurodegeneration

Alzheimer's Disease

TrkA plays a complex role in Alzheimer's disease pathogenesis:

Cholinergic Neuron Survival: NGF/TrkA signaling supports basal forebrain cholinergic neurons that degenerate early in AD[3]
Amyloid-beta Interactions: [Abeta](/proteins/amyloid-beta) oligomers can interfere with NGF/TrkA signaling
[Tau](/proteins/tau) Pathology: TrkA dysfunction may contribute to tau hyperphosphorylation
Therapeutic Potential: NGF delivery and TrkA agonists have been investigated to protect BFCNs[4]

| Feature | Role in AD |
|---------|------------|
| BFCN survival | NGF/TrkA signaling supports cholinergic neurons |
| Synaptic plasticity | TrkA-mediated ERK signaling modulates memory |
| Abeta toxicity | Abeta can impair TrkA signaling |
| Therapeutic target | TrkA agonists may protect against neurodegeneration |

Parkinson's Disease

In Parkinson's disease, TrkA signaling may provide neuroprotection:

Dopaminergic Neuron Support: TrkA is expressed in some dopaminergic neurons
Oxidative Stress: NGF/TrkA signaling can counteract oxidative damage
[alpha-Synuclein](/proteins/alpha-synuclein): TrkA activation may protect against [alpha-synuclein](/mechanisms/alpha-synuclein) toxicity[5]

Congenital Insensitivity to Pain with Anhidrosis (CIPA)

Loss-of-function mutations in NTRK1 cause CIPA, characterized by:

Insensitivity to pain
Anhidrosis (inability to sweat)
Intellectual disability
Self-mutilation behaviors

Therapeutic Implications

TrkA Agonists

| Compound | Mechanism | Development Status |
|----------|-----------|-------------------|
| NGF (Nerve Growth Factor) | Direct TrkA agonist | Clinical trials (AD) |
| Small molecule Trk agonists | Activate TrkA | Preclinical/clinical |
| Peptide Trk agonists | Receptor activation | Research stage |
| AAV-NGF | Gene therapy | Clinical trials |

Clinical Trials

NGF infusion: Tested in AD patients to support cholinergic neurons
Cell-based NGF delivery: Encapsulated cell therapy (NTF1)
Small molecule TrkB/TrkA agonists: Being developed for neuroprotection

Challenges

[Blood-brain barrier](/entities/blood-brain-barrier) penetration
Side effects (pain, hyperinnervation)
Optimal dosing regimens
Receptor selectivity

Signaling Pathways

NGF/TrkA Signaling Cascade

Mermaid diagram (expand to render)

Cross-talk with Other Pathways

p75NTR co-receptor: NGF can also bind p75NTR, which modulates TrkA signaling
Amyloid-beta: Abeta can interfere with TrkA signaling at multiple levels
Oxidative stress: TrkA activation can induce antioxidant responses

Interacting Proteins

Ligands

[NGF](/proteins/ngf-protein) (Nerve Growth Factor)
[NT-3](/proteins/nt-3-protein) (Neurotrophin-3)
[NT-4](/proteins/nt-4-protein) (Neurotrophin-4)

Downstream Signaling

[PI3K](/proteins/pik3ca) (Phosphoinositide 3-kinase)
[AKT](/proteins/akt-protein) (Protein kinase B)
[ERK1/2](/proteins/mapk1) (Extracellular signal-regulated kinases)
[PLC-gamma](/proteins/plcg1) (Phospholipase C-gamma)

Adaptor Proteins

[SHC](/proteins/shc1) (SHC-transforming protein 1)
[Grb2](/genes/grb2) (Growth factor receptor-bound protein 2)
[SOS](/proteins/sos1) (Son of Sevenless)

Key Publications

[Barbacid M (1994) The Trk family of neurotrophin receptors. J Neurobiol 25:1386-1403](https://pubmed.ncbi.nlm.nih.gov/7840424/)

[Chao MV (2003) Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci 4:299-309](https://pubmed.ncbi.nlm.nih.gov/12671746/)

[Mufson EJ, et al. (2003) TrkA in Alzheimer's disease: Pathological changes and functional implications. Prog Brain Res 146:171-181](https://pubmed.ncbi.nlm.nih.gov/12749711/)

[Tuszynski MH, et al. (2005) Nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551-555](https://pubmed.ncbi.nlm.nih.gov/15864417/)

[Lee R, et al. (2015) Neurotrophic factors and Parkinson's disease. Parkinsons Dis 2015:564308](https://pubmed.ncbi.nlm.nih.gov/25802517/)

[Weimar IS, et al. (1998) Expression and function of TrkA in normal and malignant hematopoietic cells. Leuk Lymphoma 31:217-229](https://pubmed.ncbi.nlm.nih.gov/9722070/)

Overview

Background

The study of Trka (Tropomyosin Receptor Kinase A) (Ntrk1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

[Unknown, Barbacid M (1994). The Trk family of neurotrophin receptors. J Neurobiol 25: 1386-1403 (1994)](https://pubmed.ncbi.nlm.nih.gov/7840424/)

[Unknown, Chao MV (2003). Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci 4: 299-309 (2003)](https://pubmed.ncbi.nlm.nih.gov/12671746/)

[Mufson EJ, et al, (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12749711/)

[Tuszynski MH, et al, (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15864417/)

Lee R, et al, (2015) (2015)

Longo FM, et al, (2014) (2014)

[Weimar IS, et al, (1998) (1998)](https://pubmed.ncbi.nlm.nih.gov/9722070/)

Unknown, Indo Y (2001). Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): Mutations and polymorphisms in NTRK1 (NGEF receptor tyrosine kinase). Hum Mutat 17: 423-434 (2001)

📖 View canonical wiki page →

TrkA (Tropomyosin Receptor Kinase A) (NTRK1)

TrkA (Tropomyosin Receptor Kinase A)

Overview

Introduction

TrkA (Tropomyosin Receptor Kinase A)

Overview

Introduction

Structure

Extracellular Domain

Transmembrane Domain

Intracellular Domain

Activation Mechanism

Normal Physiological Function

Neuronal Survival and Differentiation

Tissue-Specific Functions

Non-Neuronal Functions

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Congenital Insensitivity to Pain with Anhidrosis (CIPA)

Therapeutic Implications

TrkA Agonists

Clinical Trials

Challenges

Signaling Pathways

NGF/TrkA Signaling Cascade

Cross-talk with Other Pathways

Interacting Proteins

Ligands

Downstream Signaling

Adaptor Proteins

Key Publications

See Also

Overview

Background

See Also

External Links

References